Brazil's health regulator Anvisa allows the Chinese Coronavirus vaccine to be tested
On Friday, Brazilian health regulator Anvisa approved clinical trials of a potential coronavirus vaccine developed by Sinovac in China, according to an official publication in the gazette.
The report-first announced on June 11-is led by Instituto Butantan, a state-funded research center in Sao Paulo. The agreement with Sinovac includes not only trials but technology transfer to produce the potential vaccine locally.
On June 29, Sao Paulo state Governor Joao Doria said 9,000 volunteers have already been registered to test the vaccine against COVID-19, the respiratory disease caused by the novel coronavirus.
Trials will be conducted by 12 research centers in six Brazilian states: Sao Paulo, Rio de Janeiro, Minas Gerais, Brasilia, Rio Grande do Sul and Parana, according to Doria.
Anvisa's approval comes after Brazil surpassed 1.5 million confirmed cases of COVID-19, according to Health Ministry data, the second worst outbreak after the United States. The number of deaths rose by 1,290 in the past 24 hours, bringing the total tally to 63,174, the data showed.
(REUTERS)
Comments
Post a Comment